HERZUMA

PeakmAb

trastuzumab

Celltrion

BLAINJECTIONINJECTABLE

Approved

Dec 2018

Lifecycle

Peak

Competitive Pressure

30/100

Clinical Trials

Mechanism of Action

HER2/Neu/cerbB2 Antagonists

Pharmacologic Class:

HER2/neu Receptor Antagonist

Clinical Trials (5)

NCT07413939Phase 2/3Not Yet Recruiting

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

Started Apr 2026

650 enrolled

HER2-positive Breast Cancer

NCT07198724Phase 1/2Not Yet Recruiting

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

Started Mar 2026

65 enrolled

Metastatic Breast CancerHER2 Low Breast CarcinomaHER2-negative Breast Cancer+2 more

NCT07428044Phase 2Recruiting

A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

Started Feb 2026

14 enrolled

Non-Small Cell Lung CancerNon-small Cell Lung Cancer Stage IINon-Small Cell Lung Cancer Stage IIIA+1 more

NCT06595563Phase 2Recruiting

HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer

Started Feb 2026

87 enrolled

HER2-positive Metastatic Breast CancerHER2-positive Advanced Breast Cancer

NCT06899126Phase 3Recruiting

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

Started Oct 2025

686 enrolled

Non-small Cell Lung Cancer

Company